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Abstract
Introduction The study was aimed at verifying whether the
occurrence of hypernatremia during the intensive care unit (ICU)
stay increases the risk of death in patients with severe traumatic
brain injury (TBI). We performed a retrospective study on a
prospectively collected database including all patients
consecutively admitted over a 3-year period with a diagnosis of
TBI (post-resuscitation Glasgow Coma Score ≤ 8) to a general/
neurotrauma ICU of a university hospital, providing critical care
services in a catchment area of about 1,200,000 inhabitants.
Methods Demographic, clinical, and ICU laboratory data were
prospectively collected; serum sodium was assessed an
average of three times per day. Hypernatremia was defined as
two daily values of serum sodium above 145 mmol/l. The major
outcome was death in the ICU after 14 days. Cox proportional-
hazards regression models were used, with time-dependent
variates designed to reflect exposure over time during the ICU
stay: hypernatremia, desmopressin acetate (DDAVP)
administration as a surrogate marker for the presence of central
diabetes insipidus, and urinary output. The same models were
adjusted for potential confounding factors.
Results We included in the study 130 TBI patients (mean age
52 years (standard deviation 23); males 74%; median Glasgow
Coma Score 3 (range 3 to 8); mean Simplified Acute Physiology
Score II 50 (standard deviation 15)); all were mechanically
ventilated; 35 (26.9%) died within 14 days after ICU admission.
Hypernatremia was detected in 51.5% of the patients and in
15.9% of the 1,103 patient-day ICU follow-up. In most instances
hypernatremia was mild (mean 150 mmol/l, interquartile range
148 to 152). The occurrence of hypernatremia was highest (P
= 0.003) in patients with suspected central diabetes insipidus
(25/130, 19.2%), a condition that was associated with
increased severity of brain injury and ICU mortality. After
adjustment for the baseline risk, the incidence of hypernatremia
over the course of the ICU stay was significantly related with
increased mortality (hazard ratio 3.00 (95% confidence interval:
1.34 to 6.51; P = 0.003)). However, DDAVP use modified this
relation (P  = 0.06), hypernatremia providing no additional
prognostic information in the instances of suspected central
diabetes insipidus.
Conclusions Mild hypernatremia is associated with an
increased risk of death in patients with severe TBI. In a
proportion of the patients the association between
hypernatremia and death is accounted for by the presence of
central diabetes insipidus.
Introduction
Hypernatremia, a water balance disorder encountered in
about 6 to 9% of critically ill patients, has been associated with
an increased risk of death and complications in some recent
retrospective studies in general intensive care units (ICUs) [1-
3].
Patients with severe traumatic brain injury (TBI) have a high
risk of developing hypernatremia over the course of their ICU
stay, due to the coexistence of predisposing conditions such
as impaired sensorium, altered thirst, central diabetes insip-
idus (CDI) with polyuria, and increased insensible losses [4].
Moreover, these patients often receive mannitol or hypertonic
CDI: central diabetes insipidus; CT: computed tomography; DDAVP: desmopressin acetate; ICU: intensive care unit; ICP: intracranial pressure; 
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saline solutions, with the aim of reducing cerebral edema and
controlling intracranial pressure [5]. In this clinical setting, it is
not known, however, whether increased serum sodium (Na) is
an independent risk factor for death, or is simply a surrogate
marker of illness severity.
It has been shown that almost 20% of patients with subarach-
noid hemorrhage develop hypernatremia, a complication bear-
ing an increased risk of death [6]. On the other hand, in a
recent series of patients from a neuro-ICU, hypernatremia was
documented in only 8% of them; moreover, only the more
advanced forms of this disorder (that is, serum Na exceeding
160 mmol/l) were associated with increased mortality [7].
These conflicting findings leave the question of the true clinical
significance of moderate increases in serum Na (for example,
between 145 and 160 mmol/l) unresolved.
We therefore designed the present study in order to verify
whether the occurrence of hypernatremia during the ICU stay
is an independent risk factor of death in patients with severe
TBI (Glasgow Coma Score ≤ 8).
Materials and methods
Study population
We studied all adult patients consecutively admitted with a
diagnosis of severe TBI from May 2004 to April 2006. The
operational definition of severe TBI was a post-resuscitation
Glasgow Coma Score of 8 or less at ICU admission.
The ICU of the Anesthesia and Intensive Care Department is
located in part of the 1,200-bed Parma University Medical
School Hospital, a tertiary academic referral institution. The
ICU contains 20 general intensive care beds, staffed with full-
time intensive care specialists. The unit provides all critical
care services to patients admitted to the Emergency Depart-
ment for head injury with or without polytrauma, as well as
postoperative care for the neurosurgery services. The same
ICU serves as a neurotrauma ICU for a catchment area of
about 1,200,000 inhabitants.
Data collection
Regarding the TBI patients admitted to the ICU, we prospec-
tively collected data concerning demography, clinical and lab-
oratory characteristics, prognostic factors and outcome,
which were entered into an electronic database. For each
patient the following data were obtained at admission: age,
sex, cause of admission classified by type of trauma, premor-
bid functional status, acute and chronic co-morbidities, brain
CT-scan data, Simplified Acute Physiology Score II score [8],
Injury Severity Score [9], Glasgow Coma Score [10], hemody-
namics, respiratory status and mechanical ventilation, blood
gases, serum electrolytes, serum glucose, hemoglobin, leuko-
cyte and platelet counts, renal function, and urinary output.
Additional data were collected on a daily basis: serum electro-
lyte levels (all values, if more than one value was available),
serum glucose, administered medications and fluids, including
vasopressin and osmotic therapy (defined as the use of 3% or
5% saline or mannitol to treat cerebral edema or raised intrac-
ranial pressure), urinary volume, mechanical ventilation, and
intracranial pressure (ICP) when available. The use of desmo-
pressin acetate (DDAVP) was taken as a surrogate marker of
suspected CDI. Finally, data concerning ICU complications,
ICU mortality and inhospital mortality were also collected.
All subjects received standard care for TBI according to cur-
rent guidelines [11,12]. The protocol dictated that routine clin-
ical practice would never change for the purpose of study data
collection. The Ethical Committee of the Parma University
Medical School approved the study and waived the need for
written informed consent by patients' next of kin.
Generation of variates and missing values
Some clinical parameters were assessed hourly, and other
parameters were assessed every 4 hours, 6 hours, 8 hours or
once daily. Serum Na was assessed an average of three times
a day. The number of determinations, however, tended to
decrease with the increase in length of the ICU stay. To sim-
plify the analysis, we created variates referring to the day of
stay as the fundamental time unit.
We adopted three indexes to define the presence of serum Na
disorders – daily serum Na, daily urinary output (polyuria being
the marker of renal water loss), and daily administration of
DDAVP.
Urinary output was the least reliable of these three indexes, as
it was frequently missing. Some of the patients did not have
complete (that is, 24-hour) urine output recorded. This prob-
lem occurred more frequently on the day that the most
severely ill patients were admitted (in fact, missing urine output
was significantly and independently associated with increased
mortality; data not shown). In some other cases, exact urine
output recording was missing during the hospital stay
because the patients received intermittent urinary catheteriza-
tion. Finally, urinary output was influenced by DDAVP medica-
tion, which the doctors administered whenever they noted an
increase in urinary output (usually, an abrupt increase of uri-
nary output to more than 250 ml/hour for 2 hours, in the
absence of diuretic therapy), with the result of curbing the
increased urinary output.
At variance with urinary output, there were only nine missing
values regarding serum Na and no missing values concerning
DDAVP use.
For the purpose of the analysis, the presence of hypernatremia
was expressed as a time-dependent indicator variate. Hyper-
natremia was defined as serum Na >145 mmol/l on at least
two occasions during 1 day of ICU stay. In 35% of the cases
there was only a single daily determination, although thisAvailable online http://ccforum.com/content/13/4/R110
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occurred for the most part during the second week of stay. The
nine missing daily Na measurements were replaced by the
value of the previous day of the ICU stay.
The use of DDAVP, which we took as a surrogate marker for
the presence of CDI, was defined by a time-dependent indica-
tor variate. To avoid the possibility that DDAVP could be inter-
preted as a marker of established brain death rather than a
death predictor, the coding of the variate switched from 0 to 1
starting from the day after the first DDAVP administration.
We also created time-dependent indicator variates for the
presence of daily urinary output above 3 l and for the use of
mannitol and hypertonic saline solutions, and created time-
dependent continuous variates for glucose levels and hyperg-
lycemia (two daily serum glucose values above 10 mmol/l).
Data analysis
We used Stata Release 10 software (2007; StataCorp, Col-
lege Station, TX, USA) for all analyses.
Fourteen-day mortality
With the use of Cox proportional-hazards regression models,
we examined the relation between 14-day ICU mortality and
hypernatremia, polyuria (defined as urinary output >3 l day),
and the use of DDAVP (that is, presence of CDI) over the
course of the ICU stay. In order to adjust the estimates for the
baseline risk of death, we used the core + CT score from the
International Mission for Prognosis and Clinical Trial (IMPACT)
prognostic model [13]. This score takes into account the
extension of brain injury detected by CT scan at admission.
Additionally, we adjusted the models for common determi-
nants of polyuria (use of hypertonic Na solutions, intravenous
mannitol, hyperglycemia), which may also be potentially asso-
ciated with increased mortality in this category of patients.
In the principal analyses, patients were censored at the time of
discharge. In a further analysis, all patients discharged from
the ICU before day 14 were considered as surviving beyond
day 14, with the exception of the patient who died at day 12
after discharge from the ICU. The covariate status after dis-
charge from the ICU was not known, thus the last covariate
before discharge was carried forward until the day of censor-
ing or death. We do not report the results of these analyses
because they were virtually identical to those of the main anal-
yses.
We examined linearity of the continuous variates by the resid-
ual-based plots [14]. We tested departures from the propor-
tional assumption using the procedure proposed by
Grambsch and Therneau based on Shoenfeld residuals [15].
We used the Efron method to handle tied failures, the likeli-
hood ratio test to compute P values, the profile likelihood for
the point estimate and 95% confidence intervals [16].
We also decided to estimate the relation between hyper-
natremia and death after having stratified the data according
to the presence of suspected CDI (that is, DDAVP use). With
this aim in mind we fitted an interaction term between DDAVP
use and hypernatremia in a stratified Cox regression model
where DDAVP use was included as the stratum variable. To
gain deeper insight into the nature of the observed relation
between hypernatremia and mortality in the presence of CDI,
we computed a measurement to explain variation in survival
time (namely, R2), which is appropriate for use with the unstrat-
ified Cox regression models with time-dependent covariates.
For this purpose we used the strph2 program, which com-
putes Rosyton's modification of O'Quingley, Xu and Stare's
modification of Nagelkerke's coefficient of determination for
survival models [17,18].
We also compared the models with the Bayes information cri-
terion. The model with the smallest value of the Bayes informa-
tion criterion was considered better. The Bayes information
criterion is a likelihood-based measure of fit, which adds a pen-
alty for added covariates based on sample size. It seeks to bal-
ance the competing desire of finding the best model (in terms
of maximizing the likelihood) with model parsimony (only
including those covariates that significantly contribute to the
model). For the computation of the Bayes information criterion
we considered the sample size to be equal to 130 (that is, the
number of patients).
Other analyses
Two-sample comparisons were performed by the t test or the
Mann–Whitney test for the continuous variates, and by
Fisher's exact test for the categorical variates. Mixed models
(with patients fitted at random) were used for two-sample
comparisons in the presence of repeated measurements. The
variates were log-transformed whenever appropriate to
improve normality. The within-subject association between the
incidence of hypernatremia and DDAVP administration was
examined with exact conditional logistic regression (with the
patient fitted as the stratum variable). The between-subject
cross-sectional association between DDAVP and hyper-
natremia (with the 130 patients classified according to the
occurrence, at any time during the ICU stay, of hypernatremia
or DDAVP administration) was examined with exact uncondi-
tional logistic regression. All reported P values are two tailed.
Results
Clinical characteristic of the study population, follow-up 
and mortality
We enrolled 130 patients with severe TBI. The characteristics
of the population in our study are summarized in Table 1. All
patients were mechanically ventilated, about one-half of them
by tracheostomy. Only 52 patients (40%) suffered from an iso-
lated TBI, while about one-half of the others also had thoracic
trauma with lung involvement. A relevant proportion of the
patients had skull fracture, brain contusion, or subarachnoidCritical Care    Vol 13 No 4    Maggiore et al.
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hemorrhage. Thirty-two patients had no pupillary light reflex at
admission. CT scan at admission showed cerebral swelling
with a midline shift in one-quarter of the patients (median shift,
10 mm) and cerebral herniation in about one-sixth of them.
Forty-one percent underwent neurosurgical emergent proce-
dures after admission to the ICU. Only 5% of the patients were
severely hypotensive at admission, but about one-half of them
required vasopressor administration during their ICU stay.
Of the 130 patients, 34 (26.2%) died in the ICU within 14
days after admission, after a total follow-up of 1,103 patient-
days. One patient died on day 12 (that is, within 14 days after
admission), when he had been already discharged from the
ICU. Twenty-nine of the 34 deaths in the ICU occurred within
3 days after admission. Eleven patients were discharged from
the ICU within 3 days, and another 42 patients were dis-
charged between day 4 and day 14. The total inhospital mor-
tality was 41/130 (31.5%).
Hypernatremia during the ICU stay
The mean serum Na at admission was 139 mmol/l (standard
deviation 3.9). Only three patients (2.3%) had serum Na above
145 mmol/l (maximum value 149 mmol/l). Altogether, 15.9%
of the follow-up days were complicated by hypernatremia –
occurring at least once in 51.5% of the patients for 31.0% of
the duration of their stay in the ICU, even though it was mild.
In fact, the highest serum Na in patients with hypernatremia
was, on average, 150 mmol/l (range 146 to 164, interquartile
range 148 to 152).
Urinary output was missing in 153 out of the 1,103 ICU days
of follow-up. Unfortunately, the data on urinary output were not
randomly missing. In fact, ICU mortality in patients with at least
one missing urinary output was 51.2% (21/41), in comparison
with 16.8% (15/89) in the remaining patients (P < 0.001).
Polyuria was detected in 34.4% (327/950) of ICU days, and
occurred in 76.0% of the 108 subjects in whom urinary output
was recorded. In the instances of ascertained polyuria, the
mean urinary output was 4,150 ml/day – the maximum being
8,850 ml/day.
Twenty-five patients (19.2%) received DDAVP at least once
over the course of their ICU stay. DDAVP, however, was
administered only during 5.9% of the days of the entire follow-
up. Patients receiving DDAVP had a higher urinary output and
serum Na than those not receiving this medication (median uri-
nary output 3,720 vs. 2,480 ml/day, P < 0.001; median serum
Na 148 vs. 142 mmol/l, P < 0.001). For each patient the prob-
ability of receiving DDAVP increased with the onset of hyper-
natremia (odds ratio = 3.41, P = 0.009 by conditional logistic
regression). Accordingly, 29.9% (20/67) of the patients who
developed hypernatremia at any time during their ICU stay
received DDAVP, compared with 7.9% (5/63) of the others
(odds ratio = 4.88, P = 0.003 by unconditional logistic regres-
sion).
Table 1
Clinical and demographic characteristics at intensive care unit 
admission
Age (years) 51.8 (23)
Male gender 96 (74%)
Injury Severity Score 30.3 (7.7)
Simplified Acute Physiology Score II Score 49.8 (14.6)
Glasgow Coma Score 3 (3 to 8)
Motor score 1 (1 to 5)
1 78 (60.0%)
21 1  ( 8 . 5 % )
31 1  ( 8 . 5 % )
46  ( 4 . 6 % )
5 24 (18.5%)
Absence of pupillary reflex
Both 21 (16.2%)
One 11 (8.5%)
Systolic arterial pressure <90 mmHg 7 (5.4%)
Tracheal intubation
Prehospital 105 (81.0%)
At admission 25 (19.2%)
Hypotension 16 (12.3%)
Diabetes 9 (6.9%)
History of heart disease 21 (16.2%)
History of arterial hypertension 24 (18.5%)
Chronic renal failure 1 (0.8%)
spO2 (pulse oxymetry) (%) 97.3 (5.7%)
Hypoxia 11 (8.5%)
Plasma HCO3 (mmol/l) 21.1 (3.4)
pCO2 (mmHg) 38.9 (7.7)
Midline shift on brain CT 32 (24.6%)
Cerebral edema on brain CT 31 (23.8%)
Cerebral herniation on brain CT 21 (16.2%)
Subarachnoid hemorrhage 62 (47.7%)
Epidural hematoma 19 (14.6%)
Presence of petechial hemorrhages 15 (11.5%)
Subdural hematoma 72 (55.4%)
Cerebral contusion 67 (51.5%)
Obliteration of the third ventricle or basal cisterns 31 (23.8%)
CT classification
I 13 (10%)
II 6 (4.6%)
III/IV 9 (6.9%)
V/VI 102 (78.5%)
Urgent neurosurgerya 54 (41.5%)
Polytrauma 78 (60.0%)
Thoracic trauma 89 (68.5%)
Abdominal trauma 25 (29.2%)
Continuous variates presented as mean (standard deviation) or 
median (range); categorical variates presented as number 
(percentage). aWithin 4 hours after intensive care unit admission.Available online http://ccforum.com/content/13/4/R110
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Figure 1 reports the crude data regarding the highest daily
serum Na recorded over the patients' ICU stay. Serum Na is
reported as a red dot or a blue circle according to whether
DDAVP was administered on the same ICU day of stay. The
relation between DDAVP and high serum Na was not evident
during the final days of ICU stay, possibly owing to the lower-
ing effect of DDAVP on serum Na.
Overall, these analyses suggest that DDAVP was, in fact, used
whenever the physician in charge of the patient's care sus-
pected CDI. Notably, the administration of DDAVP during the
ICU stay was also associated with severe brain injury at admis-
sion (data not shown).
Mannitol was administered in 49.2% (64/130) of the patients
over 27.9% (308/1,103) of the days spent in the ICU. Hyper-
tonic saline solutions were administered in 36.1% (47/130)
patients and over 14.3% (158/1,103) of the days they spent
in the ICU. These interventions did not bear any apparent rela-
tion to serum Na or DDAVP administration (data not shown).
The 51 patients in whom the concomitant measurement of
serum Na and ICP was available did not show any difference
in ICP according to the presence of hypernatremia (median
ICP 16 mmHg in both instances, P = 0.67).
The average of the daily mean serum glucose was 7.7 mmol/l
(range 3.3 to 17.0). Hyperglycemia occurred at least once in
37.7% (46/130) of the patients during 7.7% (85/1,103) days
of stay in the ICU. There was no significant difference in mean
glucose levels and in the rate of hyperglycemia according to
DDAVP use or the presence of hypernatremia (data not
shown).
Relation between hypernatremia and ICU mortality
Patients who died on days 2 and 3 of their ICU stay had the
highest increase in daily average serum Na between days 1
and 2, while receiving DDAVP more often than the others. In
fact, the 13 patients who died on day 2 had a mean increase
of serum Na of +3.7 mmol/l, which was higher than that
observed in the same period in the 103 patients still alive in the
ICU on day 2 (+1.5 mmol/l; P = 0.020). The mean increase in
the four patients who died on day 3 was +4.6 mmol/l; that is,
greater than that observed in the 96 patients who were still
alive in the ICU on day 3 (+1.4 mmol/l; P = 0.019). Accord-
ingly, patients who died on days 2 and 3 had received DDAVP
more frequently than those who remained alive in the ICU. In
fact, on day 2 the proportion of DDAVP use was 3/13 (23.1%)
among patients who died and was 3/103 (2.9%) among those
who were still alive (P = 0.018). On day 3, this proportion of
DDAVP use was 3/4 (75.0%) and 4/96 (4.2%), respectively
(P  = 0.001). Overall, 56% (14/25) of the patients who
received DDAVP at any time during their ICU stay died, com-
pared with 19.0% (20/105) of the others (P = 0.001).
These findings were mirrored by the results of Cox propor-
tional-hazards regression analysis. As shown in Table 2, hyper-
natremia was associated with a threefold increase in the
hazard of ICU death even after adjustment for baseline risk
(hazard ratio = 3.00 (95% confidence interval: 1.34 to 6.51; P
= 0.003)). The additional adjustment for DDAVP use, how-
ever, halved the estimated relative increase in mortality (hazard
ratio of hypernatremia adjusted for DDAVP use = 2.04; P =
0.092). On the other hand, after adjustment for hypernatremia,
the hazard ratio associated with DDAVP use was 3.88 (P =
0.005) (Table 2). The R2 values of the model that included the
baseline risk were 0.543, 0.596, and 0.624 for hypernatremia,
for DDAVP, and for hypernatremia + DDAVP, respectively. As
shown in Table 2, after stratifying the model according to
DDAVP use (that is, presence of suspected CDI), hyper-
natremia did not bear any additional prognostic information in
the presence of CDI (hazard ratio = 0.58; P = 0.57), while
retaining its importance in the other instances (hazard ratio =
4.20; P = 0.004) (P = 0.060 for the test of the difference
between the two hazard ratios).
Additional adjustment for the use of mannitol, hypertonic saline
solution and hyperglycemia did not change the findings (data
not shown). In fact the latter, which was associated with
increased mortality, was evenly distributed according to the
presence of hypernatremia and the use of DDAVP (data not
shown).
Figure 1
Highest daily serum sodium during the intensive care unit stay Highest daily serum sodium during the intensive care unit stay. Serum 
sodium (Na) values measured during intensive care unit (ICU) days 
when desmopressin acetate (DDAVP) was not administered (red dots) 
and when DDAVP was administered (blue circles). Data reported in the 
upper part of the plot represent the number of patients under observa-
tion on each ICU day of stay (the number decreases from left to right 
owing to discharge from ICU or owing to patient death). Horizontal dot-
ted line, cut-off level of 145 mmol/l used to define hypernatremia. 
DDAVP was associated with higher serum Na levels (P < 0.001). The 
association between DDAVP and hypernatremia was not evident in the 
latest period of the ICU stay, possibly owing to the lowering effect of 
DDAVP on serum Na.Critical Care    Vol 13 No 4    Maggiore et al.
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Discussion
To our knowledge, the present study is the first that has been
specifically aimed at investigating the incidence and clinical
significance of hypernatremia occurring during the course of
the ICU stay in a large series of patients with severe TBI. The
study shows that, in the immediate post-TBI period, mild
hypernatremia is associated with an increased risk of death –
although, in a proportion of the patients, this association is due
to the occurrence of CDI, a marker of the extension and sever-
ity of brain injury.
We acknowledge that our study has the significant weakness
of using DDAVP as the major criterion for diagnosing CDI,
which, at best, can be considered a surrogate index only. Agha
and colleagues defined CDI in the immediate post-TBI as
serum Na >145 mmol/l in the presence of both polyuria (>3.5
l/day) and diluted urine (osmolality < 300 mOsm/l) [19,20].
We could not use the same criteria for the diagnosis of CDI, in
as much as data on urinary output were missing in many
instances and urine osmolality was not measured. Our analy-
ses, however, showed a CDI incidence of 19.2% (25/130);
that is, well within the range of 15 to 26% documented by the
previous studies on the subject [19-21]. This concordant find-
ing suggests that in our series CDI was correctly classified. In
another small series of TBI patients the incidence of CDI was
much lower [22], probably owing to the exclusion of patients
with incomplete data. Similarly to those studies, we found that
CDI is associated with an increase in the severity of brain injury
[19] and in the risk of death [21,22]. Finally, our analysis was
adjusted for several factors potentially capable of confounding
the relation between hypernatremia, CDI and mortality;
namely, the use of hypertonic saline solution, intravenous man-
nitol, serum glucose levels, and the incidence of hyperglyc-
emia [23-25].
The high incidence of CDI that both we and other workers
found [19-21] is not unexpected in patients with TBI [26]. The
awareness of the importance of CDI is such that a decade ago
a small randomized controlled study was designed to evaluate
whether or not the use of DDAVP in all brain-dead donors (by
definition, in patients with the most severe degree of brain
injury) could improve kidney transplant function [27,28]. Injury
of the hypothalamus and pituitary generally occurs concomi-
tantly, and is seen at autopsy in up to 60% of patients dying
from head trauma [22]. Edwards and Clark reviewed a series
of pathological studies of fatal head injury and reported that
hemorrhage or infarction in the hypothalamus was detected in
42% of cases [29]. The petechial hemorrhage areas in the
anterior hypothalamic nuclei and neurohypophysis can be
caused by forces transmitted to the head on impact, by
increased ICP resulting from the brain edema, by shearing
stresses that produce disruption of the pituitary stalk, and by
the hypothalamic–hypophyseal portal system [30].
Our results confirm the recent finding from Hadjizacharia and
colleagues that CDI is an independent risk indicator of death
Table 2
Disorder of water balance over the course of the ICU stay and ICU mortality
Variate Hazard ratio 95% confidence interval P value Bayes information criteriona
Crude analysis
Hypernatremia 3.34 1.55 to 6.88 0.002 313.29
DDAVP use 8.23 3.24 to 19.52 <0.001 304.75
Adjusted for baseline risk of death
Hypernatremia 3.00 1.34 to 6.51 0.003 291.17
DDAVP use 5.48 2.13 to 13.21 <0.001 286.07
Adjusted for baseline risk of death and for each other
Hypernatremia 2.04 0.81 to 4.84 0.092 288.09
DDAVP use 3.88 1.40 to 10.33 0.005
Hypernatremia adjusted for baseline risk and stratified according to DDAVP use
Hypernatremia with DDAVP use 0.58 0.07 to 3.67 0.57 256.53
Hypernatremia without DDAVP use 4.20 1.62 to 10.17 0.004
Hazard ratio, 95% confidence intervals, and P values associated with hypernatremia and desmopressin acetate (DDAVP) use in the intensive care 
unit (ICU), estimated by six different Cox proportional-hazards regression models. Hazard ratios associated with hypernatremia and DDAVP use 
were first estimated in separate models, without adjusting for confounding factors (Crude analysis), and after adjusting for baseline risk (Adjusted 
for baseline risk of death). They were then estimated including hypernatremia and DDAVP use in the same model in order to isolate the effect of 
each variate independently of the other (Adjusted for baseline risk of death and for each other). Finally, the hazard ratio associated with 
hypernatremia was estimated stratifying the Cox regression model for DDAVP use (Hypernatremia adjusted for baseline risk and stratified 
according to DDAVP use). Baseline risk is represented by the score from the International Mission for Prognosis and Analysis CT prognostic 
model [11]. aA measure of both model fit and parsimony; the better the model, the smaller the associated BIC value.Available online http://ccforum.com/content/13/4/R110
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[21]. In fact, in our study the presence of CDI provided addi-
tional prognostic information regarding the extension of brain
injury with respect to the CT scan at admission, because the
relative hazard of mortality associated with CDI was adjusted
for the CT IMPACT prognostic model as assessed at ICU
admission. We found that the incidence of hypernatremia
(occurring in about one-half of the patients at any time during
the ICU stay, with 16% of ICU days complicated by this
sodium disorder) was more than double the incidence of CDI.
This incidence is higher than that reported by Qureshi and col-
leagues (19%) [6] and by Wartenberg and colleagues (22%)
[31,32]. The latter two series, however, included patients with
subarachnoid hemorrhage rather than with TBI; moreover, the
study by Qureshi and colleagues defined hypernatremia by
serum Na at admission or on day 3, and the study by Warten-
berg defined hypernatremia as serum Na >150 mmol/l.
Another study from a very large database (The Traumatic
Coma Data Bank) reported an occurrence of electrolyte
abnormalities in patients affected by TBI as high as 59%, with
a peak incidence in the first 24 to 96 hours [33]; unfortunately,
the true incidence of hypernatremia cannot be inferred from
the data presented in the study, as all types of electrolyte dis-
turbances were pooled together.
To our knowledge, ours is the first study documenting the inci-
dence of hypernatremia during the ICU stay in severe TBI
patients. The definition of hypernatremia in our study refers to
the first 14 days of ICU stay, and it is robust since it requires
that at least two values of serum Na be >145 mmol/l in all
patients receiving multiple daily determinations of serum
sodium. The finding that the incidence of CDI was lower than
that of hypernatremia suggests that only a minority of the
cases of hypernatremia were due to CDI. In most cases hyper-
natremia was generally mild, probably because the prompt
administration of DDAVP by the attending physician prevented
excess water loss if CDI was present. Van Beek and col-
leagues recently examined the relation between serum Na and
outcome using data from the IMPACT database [34]. Their
analysis took into consideration only serum Na values at
admission, however, not those obtained during the ICU stay.
At variance with what is observed during the ICU stay, patients
with TBI show hypernatremia only rarely at admission, which in
fact was detected only in 5% of the patients of the IMPACT
study and in 2.3% of the patients in our study. In that setting
Van Beek and colleagues defined high serum Na as Na levels
above the 75th percentile, corresponding to 142 mmol/l [34];
that is, a level lower than the standard cut-off value currently
used for defining hypernatremia.
Our findings indicate that in a proportion of the patients the
relation between hypernatremia and mortality is accounted for
by the coexistence of CDI, whereas hypernatremia by itself
could represent an independent risk factor of death in those
patients lacking CDI. We recognize that our criteria for assess-
ing CDI might have identified only its full blown forms, how-
ever, possibly leaving undetected those incomplete and subtle
forms that still can cause hypernatremia; this might explain the
residual relation we found between hypernatremia and death.
Further studies are needed to provide support for this hypoth-
esis.
Finally, the relation between hypernatremia and mortality has
been already documented in studies mostly dealing with
patients in general ICUs [1-3,35,36], and not specifically
including TBI patients. Even on the basis of the more recent lit-
erature, unfortunately based on retrospective studies only [1-
3], it is not however possible to definitely exclude the possibil-
ity that hypernatremia in the ICU could simply be regarded as
a surrogate marker of illness severity, rather than as an inde-
pendent predictor of mortality. In the case of patients with TBI
the interpretation of the relation between high serum Na levels
and outcome is made even more difficult by the presence of
peculiar interfering factors – such as for example CDI, as pre-
viously discussed – and the use of hypertonic saline to control
cerebral edema and elevated ICP [5,33,37-43]. Hypertonic
saline has actually gained major interest as a treatment option
in patients with elevated ICP levels due to a wide spectrum of
etiologies, such as subarachnoid hemorrhage [44-47], stroke
[48,49], elective brain surgery [50], as well as other clinical
conditions characterized by cerebral edema [51-53]. The pro-
posed mechanisms of hypertonic saline action are complex,
involving cell volume reduction due to fluid drawing from the
brain, reduced cerebral blood volume due to ameliorated
blood viscosity and rheology, greater neuroprotection through
the restoring of neuronal membrane potentials, neuroinflam-
matory pathway modulation, and so forth [54].
It is to be noted that most available data about hypertonic
saline use (either as intravenous boluses or continuous infu-
sion) in TBI patients with high ICP levels derive from small tri-
als, case series or retrospective studies [55-59], while only
few papers deal with its possible side effects. Following the
recent publication of a retrospective analysis of neurocritically
ill patients including severe TBI [59], some concern has been
raised about the use of continuous-infusion hypertonic saline
[54]. In that study, hypertonic saline use increased the risk of
hypernatremia, increased the number of infection days,
increased the hospital length of stay, increased the creatinine
and blood urea nitrogen serum levels, along with increasing
the occurrence of deep vein thrombosis – the most severe
form (serum Na >160 mmol/l) being eventually associated
with an increased mortality [59]. Clearly, before recommend-
ing such treatment in clinical practice [60], we strongly need
randomized-control intervention studies to confirm the safety
and efficacy of hypertonic saline in the care of neurocritically ill
patients.
Conclusions
Mild hypernatremia is frequently encountered in patients with
severe TBI during the ICU stay. In this clinical setting, a pro-Critical Care    Vol 13 No 4    Maggiore et al.
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portion of the cases of hypernatremia is probably due to the
onset of CDI – an independent marker of brain injury severity
and an independent prognostic indicator of ICU death. Be this
and/or other mechanisms at play, hypernatremia is anyhow
independently related with an increased risk of death.
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